Mileshkin, Linda <br/><br/>
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.  [electronic resource] 

 -  Gynecologic oncology  07 2019 
 - 29-37 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2019.05.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anastrozole--therapeutic use<br/>Endometrial Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Middle Aged<br/>Neoplasm Staging<br/>Progression-Free Survival<br/>Quality of Life<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism